The microeconomics of personalized medicine: today's challenge and tomorrow's promise
- 20 March 2009
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 8 (4), 279-286
- https://doi.org/10.1038/nrd2825
Abstract
'Personalized medicine' promises to increase the quality of clinical care and, in some cases, decrease health-care costs. Despite this, only a handful of diagnostic tests have made it to market, with mixed success. Historically, the challenges in this field were scientific. However, as discussed in this article, with the maturation of the '-omics' sciences, it now seems that the major barriers are increasingly related to economics. Overcoming the poor microeconomic alignment of incentives among key stakeholders is therefore crucial to catalysing the further development and adoption of personalized medicine, and we propose several actions that could help achieve this goal.Keywords
This publication has 4 references indexed in Scilit:
- Polymorphism in KIF6 Gene and Benefit From Statins After Acute Coronary SyndromesJournal of the American College of Cardiology, 2008
- A Kinesin Family Member 6 Variant Is Associated With Coronary Heart Disease in the Women’s Health StudyJournal of the American College of Cardiology, 2008
- Association of the Trp719Arg Polymorphism in Kinesin-Like Protein 6 With Myocardial Infarction and Coronary Heart Disease in 2 Prospective TrialsJournal of the American College of Cardiology, 2008
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006